What is the most effective strategy for managing diabetic dyslipidaemia?

Charles A. Reasner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The dyslipidaemic profile of diabetes greatly contributes to the increased cardiovascular risk associated with the disorder, and evidence from many intervention trials using statins, fibrates, nicotinic acid or a nicotinic acid-statin combination, indicates the substantial cardiovascular risk reduction to be gained from lipid modification. Several large statin trials have demonstrated the efficacy of cholesterol-lowering in individuals with coronary heart disease and raised low-density lipoprotein-cholesterol (LDL-C) (≥130 mg/dL; ≥3.4 mmol/L), but for the 40% of patients whose LDL-C is within recommended limits, many of whom have low high-density lipoprotein-cholesterol (HDL-C), an alternative strategy is necessary if excess risk is to be minimized. The veterans affairs high-density lipoprotein cholesterol intervention trial (VA-HIT) proved the efficacy of the fibric acid derivative, gemfibrozil, to elevate HDL-C and reduce triglycerides, with a resulting 22% relative risk reduction for cardiovascular death or non-fatal myocardial infarction, and even greater reductions in individuals with insulin resistance and diabetes. Increased HDL-C was independently predictive of reduction in coronary heart disease. In the Coronary Drug Project, individuals with diabetes or insulin resistance derived as much as 70% cardiovascular risk reduction from the HDL-C elevations achieved with nicotinic acid therapy. The effects of lowering LDL-C and raising HDL-C are additive and predictive of total cardiovascular event reduction, and by using statin-nicotinic acid combination therapy, cardiovascular risk reductions as great as 90% are possible. Such combination strategies offer patients the greatest opportunity for improved cardiovascular health and are likely to become the treatment strategy of the future.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalAtherosclerosis Supplements
Volume6
Issue number3 SPEC. ISS.
DOIs
StatePublished - Sep 2005

Fingerprint

Dyslipidemias
HDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Niacin
Risk Reduction Behavior
LDL Cholesterol
Fibric Acids
Coronary Disease
Insulin Resistance
Gemfibrozil
Veterans
Triglycerides
Therapeutics
Myocardial Infarction
Cholesterol
Lipids
Health
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • HDL-C
  • LDL-C
  • Nicotinic acid
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

What is the most effective strategy for managing diabetic dyslipidaemia? / Reasner, Charles A.

In: Atherosclerosis Supplements, Vol. 6, No. 3 SPEC. ISS., 09.2005, p. 21-27.

Research output: Contribution to journalArticle

Reasner, Charles A. / What is the most effective strategy for managing diabetic dyslipidaemia?. In: Atherosclerosis Supplements. 2005 ; Vol. 6, No. 3 SPEC. ISS. pp. 21-27.
@article{6bdf0c0cb21c4d8a915d37d57d8c15f4,
title = "What is the most effective strategy for managing diabetic dyslipidaemia?",
abstract = "The dyslipidaemic profile of diabetes greatly contributes to the increased cardiovascular risk associated with the disorder, and evidence from many intervention trials using statins, fibrates, nicotinic acid or a nicotinic acid-statin combination, indicates the substantial cardiovascular risk reduction to be gained from lipid modification. Several large statin trials have demonstrated the efficacy of cholesterol-lowering in individuals with coronary heart disease and raised low-density lipoprotein-cholesterol (LDL-C) (≥130 mg/dL; ≥3.4 mmol/L), but for the 40{\%} of patients whose LDL-C is within recommended limits, many of whom have low high-density lipoprotein-cholesterol (HDL-C), an alternative strategy is necessary if excess risk is to be minimized. The veterans affairs high-density lipoprotein cholesterol intervention trial (VA-HIT) proved the efficacy of the fibric acid derivative, gemfibrozil, to elevate HDL-C and reduce triglycerides, with a resulting 22{\%} relative risk reduction for cardiovascular death or non-fatal myocardial infarction, and even greater reductions in individuals with insulin resistance and diabetes. Increased HDL-C was independently predictive of reduction in coronary heart disease. In the Coronary Drug Project, individuals with diabetes or insulin resistance derived as much as 70{\%} cardiovascular risk reduction from the HDL-C elevations achieved with nicotinic acid therapy. The effects of lowering LDL-C and raising HDL-C are additive and predictive of total cardiovascular event reduction, and by using statin-nicotinic acid combination therapy, cardiovascular risk reductions as great as 90{\%} are possible. Such combination strategies offer patients the greatest opportunity for improved cardiovascular health and are likely to become the treatment strategy of the future.",
keywords = "Combination therapy, HDL-C, LDL-C, Nicotinic acid, Statins",
author = "Reasner, {Charles A.}",
year = "2005",
month = "9",
doi = "10.1016/j.atherosclerosissup.2005.06.005",
language = "English (US)",
volume = "6",
pages = "21--27",
journal = "Atherosclerosis Supplements",
issn = "1567-5688",
publisher = "Elsevier Ireland Ltd",
number = "3 SPEC. ISS.",

}

TY - JOUR

T1 - What is the most effective strategy for managing diabetic dyslipidaemia?

AU - Reasner, Charles A.

PY - 2005/9

Y1 - 2005/9

N2 - The dyslipidaemic profile of diabetes greatly contributes to the increased cardiovascular risk associated with the disorder, and evidence from many intervention trials using statins, fibrates, nicotinic acid or a nicotinic acid-statin combination, indicates the substantial cardiovascular risk reduction to be gained from lipid modification. Several large statin trials have demonstrated the efficacy of cholesterol-lowering in individuals with coronary heart disease and raised low-density lipoprotein-cholesterol (LDL-C) (≥130 mg/dL; ≥3.4 mmol/L), but for the 40% of patients whose LDL-C is within recommended limits, many of whom have low high-density lipoprotein-cholesterol (HDL-C), an alternative strategy is necessary if excess risk is to be minimized. The veterans affairs high-density lipoprotein cholesterol intervention trial (VA-HIT) proved the efficacy of the fibric acid derivative, gemfibrozil, to elevate HDL-C and reduce triglycerides, with a resulting 22% relative risk reduction for cardiovascular death or non-fatal myocardial infarction, and even greater reductions in individuals with insulin resistance and diabetes. Increased HDL-C was independently predictive of reduction in coronary heart disease. In the Coronary Drug Project, individuals with diabetes or insulin resistance derived as much as 70% cardiovascular risk reduction from the HDL-C elevations achieved with nicotinic acid therapy. The effects of lowering LDL-C and raising HDL-C are additive and predictive of total cardiovascular event reduction, and by using statin-nicotinic acid combination therapy, cardiovascular risk reductions as great as 90% are possible. Such combination strategies offer patients the greatest opportunity for improved cardiovascular health and are likely to become the treatment strategy of the future.

AB - The dyslipidaemic profile of diabetes greatly contributes to the increased cardiovascular risk associated with the disorder, and evidence from many intervention trials using statins, fibrates, nicotinic acid or a nicotinic acid-statin combination, indicates the substantial cardiovascular risk reduction to be gained from lipid modification. Several large statin trials have demonstrated the efficacy of cholesterol-lowering in individuals with coronary heart disease and raised low-density lipoprotein-cholesterol (LDL-C) (≥130 mg/dL; ≥3.4 mmol/L), but for the 40% of patients whose LDL-C is within recommended limits, many of whom have low high-density lipoprotein-cholesterol (HDL-C), an alternative strategy is necessary if excess risk is to be minimized. The veterans affairs high-density lipoprotein cholesterol intervention trial (VA-HIT) proved the efficacy of the fibric acid derivative, gemfibrozil, to elevate HDL-C and reduce triglycerides, with a resulting 22% relative risk reduction for cardiovascular death or non-fatal myocardial infarction, and even greater reductions in individuals with insulin resistance and diabetes. Increased HDL-C was independently predictive of reduction in coronary heart disease. In the Coronary Drug Project, individuals with diabetes or insulin resistance derived as much as 70% cardiovascular risk reduction from the HDL-C elevations achieved with nicotinic acid therapy. The effects of lowering LDL-C and raising HDL-C are additive and predictive of total cardiovascular event reduction, and by using statin-nicotinic acid combination therapy, cardiovascular risk reductions as great as 90% are possible. Such combination strategies offer patients the greatest opportunity for improved cardiovascular health and are likely to become the treatment strategy of the future.

KW - Combination therapy

KW - HDL-C

KW - LDL-C

KW - Nicotinic acid

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=23744445265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744445265&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosissup.2005.06.005

DO - 10.1016/j.atherosclerosissup.2005.06.005

M3 - Article

VL - 6

SP - 21

EP - 27

JO - Atherosclerosis Supplements

JF - Atherosclerosis Supplements

SN - 1567-5688

IS - 3 SPEC. ISS.

ER -